by Anderson Triggs | Mar 19, 2026 | Anti-Aging News, Sterile & Non-Sterile Compounding
The Next Evolution in Regenerative Peptide Therapy When it comes to advanced recovery and regenerative medicine, few compounds have generated as much interest as BPC-157. Known for its powerful effects on muscle, tendon, ligament, and gastrointestinal healing, BPC-157...
by Anderson Triggs | May 4, 2025 | Anti-Aging News, Testosterone & Anti-Aging Therapy
In the constantly evolving landscape of male hormone optimization, few clinical challenges are as delicate as maintaining fertility while undergoing testosterone optimization therapy (TOT). Conventional wisdom and physiology tell us that exogenous testosterone...
by Anderson Triggs | Mar 8, 2025 | Anti-Aging News, Testosterone & Anti-Aging Therapy
The U.S. Food and Drug Administration (FDA) has once again reversed course on a major drug safety issue—this time, on testosterone therapy. In response to findings from the TRAVERSE clinical trial and post market ambulatory blood pressure (ABPM) studies, the FDA is...
by Anderson Triggs | Nov 19, 2024 | Anti-Aging News, Consulting Services, Testosterone & Anti-Aging Therapy
The much anticipated announcement of the Third Temporary Extension of COVID-19 Telemedicine Flexibilities for Prescription of Controlled Medications effective 15 November 2024. When Covid began the DEA needed to find a solution to allow patients access to care...
by Anderson Triggs | Oct 29, 2024 | Anti-Aging News, Sterile & Non-Sterile Compounding
On October 22, 2024, Novo Nordisk asked the FDA to add semaglutide to the demonstrably difficult to compound list. The Food and Drug Administration is proposing to establish criteria for the lists of drug products or categories of drug products that present...
